comparemela.com

Latest Breaking News On - Carll gordon - Page 5 : comparemela.com

Adicet Bio (NASDAQ:ACET) PT Lowered to $20.00

Adicet Bio (NASDAQ:ACET – Free Report) had its target price lowered by BTIG Research from $34.00 to $20.00 in a research report report published on Tuesday, The Fly reports. A number of other equities analysts also recently weighed in on ACET. HC Wainwright reiterated a buy rating and issued a $38.00 target price on shares […]

Ohio
United-states
American
Zurcher-kantonalbank-zurich-cantonalbank
Carll-gordon
Adicet-bio
Jpmorgan-chase-co
Adicet-bio-company-profile
Group-plc
Adicet-bio-inc
Securities-exchange-commission
American-century-companies-inc

Kinnate Biopharma (NASDAQ:KNTE) Receives Maintains Rating from 500.com

500.com restated their maintains rating on shares of Kinnate Biopharma (NASDAQ:KNTE – Get Rating) in a report released on Thursday, Benzinga reports. A number of other brokerages have also commented on KNTE. Stifel Nicolaus dropped their price target on Kinnate Biopharma from $8.00 to $5.00 in a research note on Tuesday, April 18th. HC Wainwright […]

United-states
Kinnate-biopharma
Stifel-nicolaus
Carll-gordon
Securities-exchange-commission
Blackrock-inc
Jpmorgan-chase-co
Metlife-investment-management
Kinnate-biopharma-company-profile
Kinnate-biopharma-inc
Goldman-sachs-group
Get-rating

Kinnate Biopharma (NASDAQ:KNTE) Price Target Cut to $24.00 by Analysts at HC Wainwright

Kinnate Biopharma (NASDAQ:KNTE – Get Rating) had its price objective trimmed by HC Wainwright from $25.00 to $24.00 in a research note released on Thursday morning, The Fly reports. A number of other research analysts have also recently issued reports on the company. Wedbush reduced their price objective on Kinnate Biopharma from $25.00 to $14.00 […]

United-states
Kinnate-biopharma
Stifel-nicolaus
Carll-gordon
Simplex-trading
Securities-exchange-commission
Goldman-sachs-group
Kinnate-biopharma-company-profile
Principal-financial-group-inc
Kinnate-biopharma-inc
Nasdaq
Get-rating

Kinnate Biopharma (KNTE) to Release Quarterly Earnings on Friday

Kinnate Biopharma (NASDAQ:KNTE – Get Rating) is scheduled to announce its earnings results on Friday, May 12th. Kinnate Biopharma (NASDAQ:KNTE – Get Rating) last posted its quarterly earnings data on Wednesday, March 15th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.02). On average, analysts […]

United-states
Jamesb-tananbaum
Carll-gordon
Kinnate-biopharma
Stifel-nicolaus
Kinnate-biopharma-inc
Barclays-plc
Squarepoint-ops
Financial-group
Kinnate-biopharma-company-profile
Goldman-sachs-group
Get-rating

vimarsana © 2020. All Rights Reserved.